Sign Up
For the best experience, choose your profession & state.
You are not currently logged in. Please log in to CEUfast to enable the course progress and auto resume features.

Course Library

Atypical Antipsychotics

2 Contact Hours - 2 Pharmacology Hours
This course is applicable for the following professions:
Advanced Registered Nurse Practitioner (ARNP), Certified Registered Nurse Anesthetist (CRNA), Clinical Nurse Specialist (CNS), Licensed Practical Nurse (LPN), Licensed Vocational Nurses (LVN), Nursing Student, Registered Nurse (RN)
This course will be updated or discontinued on or before Saturday, February 20, 2021
CEUFast Inc. did not endorse any product, or receive any commercial support or sponsorship for this course. The Planning Committee and Authors do not have any conflict of interest.
Last Updated:
Start Today
Register to enable course history
CEUfast OwlGet one year unlimited nursing CEUs $39Sign up now
To earn of certificate of completion you have one of two options:
  1. Take test and pass with a score of at least 80%
  2. Reflect on practice impact by completing self-reflection, self-assessment and course evaluation.
    (NOTE: Some approval agencies and organizations require you to take a test and self reflection is NOT an option.)
Author:    Dana Bartlett (RN, BSN, MA, MA, CSPI)

Outcomes

The use of the atypical antipsychotics is increasing, and off-label use is widespread. The atypical antipsychotics can cause serious adverse effects and administering them safely requires nurses to be aware of these adverse effects and to know the patient populations that are especially vulnerable.

Objectives

After finishing this module, the reader will be able to:

  1. Describe the mechanism of action of the atypical antipsychotics.
  2. Discuss labeled uses for the atypical antipsychotics.
  3. Identify significant adverse effects caused by the atypical antipsychotics.
  4. Discuss patient monitoring during the use of an atypical antipsychotic.
  5. Discuss nursing care issues associated with the administration of the atypical antipsychotics.

Introduction

The atypical antipsychotics are used to treat patients who have serious psychological disorders such as schizophrenia and bipolar disorder. The atypical antipsychotics, which are sometimes referred to as second-generation antipsychotics, were developed in the late ‘80s and the ‘90s as an alternative to the first-generation antipsychotic drugs such as chlorpromazine, haloperidol and thioridazine. The first –generation antipsychotics had been proven to be effective at controlling the signs and symptoms of serious psychiatric illnesses, particularly schizophrenia, but these drugs, called typical antipsychotics, can and often do cause significant adverse effects like arrhythmias, extrapyramidal symptoms (EPS) and tardive dyskinesia. These adverse effects can be irreversible and/or life-threatening.1 Because of these issues, they are dangerous when taken in overdose; a search was made for safer medications, and the atypical antipsychotics were developed. The term atypical is used because the second-generation antipsychotics are less likely to cause EPS and tardive dyskinesia, adverse effects that were commonly “typical” of the first-generation antipsychotics.2 Second-generation simply indicates that they were developed after the first-generation antipsychotics.   

In many ways, the atypical antipsychotics have been an improvement. They are relatively benign when taken in overdose,3,4 and they may be less likely to cause ventricular arrhythmias, sudden cardiac death – a well-documented adverse effect of the antipsychotics – QTc prolongation, and torsades de pointes (possibly) than the first-generation antipsychotics.5,6 They appear to be as effective and no less effective for treating schizophrenia as the first-generation antipsychotics,7,8,9 and they are less likely to cause to cause EPS 2,10,11 and tardive dyskinesia.12

However, atypical antipsychotics are associated with significant adverse effects. The atypical antipsychotics can cause EPS, and although the risk is less than for the typical antipsychotics, it is not insignificant,10 and their use is associated with tardive dyskinesia, as well. Cardiovascular, hematologic (clozapine), and metabolic complications that are potentially serious can occur, as well. In addition, atypical antipsychotics are often prescribed for vulnerable patient populations. The number of children and adolescents who are being prescribed these drugs has been increasing,13 and these patient populations may be more likely than adults to develop adverse effects.14,15

A 2013 article suggested that nurses do not have an in-depth knowledge antipsychotics: 779 direct care professionals were queried, and only 12% of the RNs could identify one serious adverse effect associated with antipsychotics.16 The use of the atypical antipsychotics is increasing, and off-label use is widespread. If these patterns continue nurses will be giving these medications more often, and they will be giving them to patients who are susceptible to the adverse effects. Knowledge of how these drugs work and what they can do will be essential for professional nurses.

Pharmacology of the atypical antipsychotics

There are 13 atypical antipsychotics available in the US. The generic name is followed by the American brand name.

Aripiprazole: Abilify®
Asenapine: Saphris®
Brexpiprazole: Rexulti®
Clozapine: Clozaril®
Iloperidone: Fanapt®
Lurasidone: Latuda®
Olanzapine: Zyprexa®
Olanzapine and fluoxetine: Symbyax®
Paliperidone: Invega®
Pimavanserin Nuplazid®
Quetiapine: Seroquel®
Risperidone: Risperdal®
Ziprasidone: Geodon®

The atypical antipsychotics are antagonists at the dopamine2 (D2) receptors, and they are antagonists at serotonin receptors, particularly the 5-HT2A receptors, and their clinical effectiveness is thought to be mediated through this receptor blockade. The differences between the first-generation antipsychotics and the atypical antipsychotics are:

  1. The degree and duration of the D2 blockade are far less, and
  2. The serotonin receptor blockade.2,17,18

These differences in D2 receptor antagonism and the serotonin receptor antagonism are thought to account for:

  1. The decreased risk of EPS, and
  2. The antipsychotic effects of these drugs

The atypical antipsychotics also bind to α1-adrenergic, histaminic, and muscarinic receptors,17 and antagonism of these receptors accounts for common side effects like drowsiness and orthostatic hypotension. The degree to which these receptors are affected is different for each drug, and the amount of receptor blockade can also be affected by the dose, e.g., the higher the dose of risperidone the greater the degree of D2 receptor blockade.19

Example: Olanzapine is a strong antagonist of the 5-HT2A, 5-HT2C, D1-4, H1, and α1-adrenergic receptors. Olanzapine is a moderate antagonist of 5-HT3 and muscarinic receptors. Given this pharmacological profile, it would be reasonable to expect that olanzapine can cause drowsiness, EPS, and orthostatic hypotension, and would be unlikely to cause anticholinergic effects.

The atypical antipsychotics are available as oral and sublingual tablets, oral liquid preparations, and parenteral preparations: aripiprazole, olanzapine, paliperidone, and risperidone are available in a long-acting IM form. There is no proven difference between the oral and long-acting injectable antipsychotics in terms of efficacy20, and for other benefits like adherence to the medication regimen, adverse effects, and hospitalization there is evidence both pro and con.20-22

Indications for Use

Most of the atypical antipsychotics have labeled indications for the treatment of adult patients who have bipolar disorder, major depressive disorder, schizophrenia, or schizo-affective disorder and some, e.g., aripiprazole have FDA approval for treating children and adolescents who have bipolar disorder, either alone or in combination with lithium, for certain signs and symptoms of autism, and for Tourette’s syndrome. The atypical antipsychotics can be used alone, as an adjunct, and for short-term and long-term therapy.

Example: The oral form of olanzapine can be used for maintenance therapy for patients who have bipolar disorder. Short-acting parenteral olanzapine can be used to treat acute agitation in patients who have schizophrenia or bipolar I disorder.

Before starting an atypical antipsychotic, the patient should be assessed for the presence of the following conditions:

  • Congenital long QT syndrome
  • Diabetes
  • Cardiovascular, hepatic, or renal disease
  • Electrolyte abnormalities
  • Medical conditions that might cause electrolyte abnormalities
  • Medications that would affect the metabolism of the atypical antipsychotic
  • Family history of torsades de pointes
  • A prolonged QTc
  • Fall risk
  • History of seizures or risk of seizures

Adverse Effects Caused by Atypical Antipsychotics

Atypical Antipsychotics and Patients with Dementia: Cerebrovascular Events and Sudden Death

Behavioral and psychological problems are common in elderly patients who have dementia.23 Non-pharmacologic treatment is preferred for controlling the behavioral and psychological problems of dementia,23,24 but the typical and the atypical antipsychotics have been and still are used for this purpose. However, this is an off-label use of these drugs, and there are two significant issues involving the atypical antipsychotics in this clinical situation.

First, there is evidence and expert opinion that atypical antipsychotics are not effective for this purpose and/or the level of effectiveness is not significant.23,25-27  

Second, the atypical antipsychotics have been associated with increased mortality in elderly patients who have dementia-related psychosis.2,23,28 An analysis by the FDA of 17 placebo-controlled trials in which most of the patients were taking atypical antipsychotics found that the risk of death in the treated patients was 1.6–1.7 times that of the patients who received a placebo (4.5% for the treated patients and 2.6% for patients receiving placebo) and that most of the deaths appeared to be from cardiovascular causes or infection.23 These findings were confirmed by a later data analysis by the FDA,28 and the prescribing information for the atypical antipsychotics contains a US Boxed Warning that states:  Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. The increased risk of mortality is greater for the first-generation antipsychotics and for the atypical antipsychotics, the risk appears to vary from drug to drug.23 There is also evidence that suggests that antipsychotics, typical and atypical, can increase the risk for myocardial infarction and stroke in patients who have dementia.23 Despite these risks and the US Boxed warning, many elderly patients are prescribed atypical antipsychotics.26

The mechanism of actions - or mechanisms – that underpin these risks are not fully known or understood.23,29  The mortality, stroke, and myocardial infarction associated with these drugs may be caused by the drugs (e.g., QTc prolongation and arrhythmias, complications of excessive sedation), by independent patient risk factors, or a combination of those two.

Movement Disorders

Movement disorders that can be caused by the atypical antipsychotics include EPS and neuroleptic malignant syndrome.

Antipsychotic-induced EPS are thought to be primarily caused by D2 dopamine receptor antagonism that creates an imbalance between dopaminergic and cholinergic tone in areas of the brain that controls motor movements.30 Extrapyramidal symptoms are a well-known adverse effect of all the antipsychotics, but they are less likely to be caused by the atypical antipsychotics (particularly tardive dyskinesia) because these drugs do not bind to the D2  receptors as strongly nor for as long.30 The risk for EPS differs between drugs: EPS are very uncommon adverse effects of clozapine and quetiapine but are very common in patients taking risperidone.2,17 Extrapyramidal symptoms include akathisia, dystonias, parkinsonism, and tardive dyskinesia.

Akathisia is characterized by intense subjective feelings of restlessness and observable repetitive movements, usually in the lower extremities, like moving from one leg to another, pacing, and leg crossing.31,32 Antipsychotic-induced akathisia usually starts several days after beginning therapy with the drug or when the dose is increased.31,32 It may also occur when the dose is decreased or when the patient discontinues use,33 and late-onset akathisia is possible.31,34

Dystonias are distinctive, abnormal, and involuntary muscle movements caused by simultaneous contractions of agonist and antagonist muscles. An antipsychotic-induced dystonic reaction is usually focal, and they can occur in any part of the body. Dystonias present as rhythmic, repetitive contractions and are characterized by twisting of body parts, abnormal movements, and abnormal postures. They usually begin several hours after taking the first dose, but delayed onset of several days is possible as well,32 and an antipsychotic-induced dystonia can occur if a second antipsychotic is prescribed or when therapy with the drug is stopped. Dystonias are uncomfortable and frightening for the patient, but aside from laryngeal dystonia, which can cause airway obstruction, they are not dangerous. As with akathisia, the reported incidence of this adverse effect varies considerably from drug to drug.

Antipsychotic-induced parkinsonism causes signs and symptoms that are essentially identical to those of Parkinson disease, including (but not limited to) bradykinesia, cogwheel rigidity, gait disturbances and neuro-psychiatric problems.32,35,36 Parkinsonism usually begins within a day to weeks after therapy begins or when the dose is increased. However, an onset of several months is possible,35 and parkinsonism may begin:

  1. When therapy with the drug is stopped;
  2. If the anticholinergic medication used to prevent EPS is stopped, or the dose is changed, or;
  3. If another dopamine receptor antagonist is added to the regimen.32

The incidence of antipsychotic-induced parkinsonism has been reported to be 20%-40%.35,37

Tardive dyskinesia is an EPS that is characterized by rhythmic, repetitive movements, most noticeably in and around the face, lips, and tongue: repetitive tongue protruding and lip-smacking are very common to this disorder. The term tardive is used because the onset of this EPS can be months or years after starting therapy with an antipsychotic.2,36  

Tardive dyskinesia is notoriously resistant to treatment, and its clinical course is very variable. If therapy with the drug continues the symptoms may stay the same, improve, or worsen, but complete remission seldom occurs,32,36 and even if therapy with the drug is stopped, complete remission may take months or years.38 The true incidence of tardive dyskinesia caused by antipsychotics is not known, but it has been reported to be between 20%-32%.36,39 The atypical antipsychotics are much less likely than the first-generation drugs to cause this adverse effect.40

Neuroleptic malignant syndrome (NMS) is a potentially lethal adverse effect of the atypical antipsychotics41-43 that is characterized by hyperthermia (>38° C), a “lead-pipe” muscular rigidity, mental status changes, and autonomic dysfunction reflected by hypertension and tachycardia.42,43 The risk for developing NMS appears to be the same for the atypical and typical and fortunately, NMS is rare: the reported incidence is 0.1%-0.3%,42 and the fatality rate is between 5%-20%.43 Neuroleptic malignant syndrome typically occurs 2-10 days after administration of a drug (a later onset can occur), and it is thought to be caused by an abrupt blockade of the D2 receptors.

Extrapyramidal symptoms are less likely to occur with the atypical antipsychotics that with the typical psychotics, there are differences between them in terms of occurrence, and rate of and for some of the second-generation drugs, the incidence of EPS is relatively low.2,44  However, less likely and low are relative terms, and the atypical antipsychotics do present what could reasonably be called a significant risk for EPS.45

Metabolic Disorders

The atypical antipsychotics can cause hyperglycemia and hyperglycemic complications, hyperlipidemia, hyperprolactinemia, and weight gain.2  

Hyperglycemia: In 2003, the FDA issued a warning that the second-generation antipsychotics have an adverse effect on glucose metabolism, and research has confirmed that the atypical antipsychotics can cause hyperglycemia, diabetic ketoacidosis (DKA)  and hyperosmolar hyperglycemic nonketotic coma, and they increase the risk of developing type 2 diabetes.46,47 Abnormal glucose metabolism in patients who take atypical antipsychotics may be caused by a direct drug effect,46 but also in part by weight gain, and by the patient’s psychiatric illness; people who have schizophrenia are more likely than the general population to develop type 2 diabetes.48 The incidence of hyperglycemia and the risk of developing type 2 diabetes from atypical antipsychotics is not known, and some of these drugs are more likely than others to affect glucose metabolism.2,49 Diabetic ketoacidosis and hyperosmolar hyperglycemic nonketotic coma are rare adverse effects of antipsychotics.50 The atypical antipsychotics may cause hyperglycemia soon after therapy with the drug is started and even after a single dose.51

Hyperlipidemia: The atypical antipsychotics can cause hyperlipidemias like elevations of fasting serum cholesterol and serum triglycerides.2 There are big differences between the atypical antipsychotics in the prevalence of dyslipidemias, e.g., dyslipidemias are common in patients taking olanzapine, but they are uncommon in patients taking aripiprazole,52,53 and the drugs that cause significant weight gain are associated with a higher risk of dyslipidemias.53 The long-term significance of this adverse effect is not clear; the cause is not fully understood, but it is likely to be a combination of direct drug effect and patient variables.2

Hyperprolactinemia: Hyperprolactinemia is a well-known adverse effect of the typical antipsychotics2 and as with the other metabolic effects, the prevalence of this adverse effect varies from drug to drug.2  Hyperprolactinemia has been associated with sexual dysfunction and with the development of certain cancers like breast cancer that may be prolactin-dependent, but according to clinical research and prescribing information, the use of atypical antipsychotics does not increase the risk of tumorigenesis.54

Weight gain: Weight gain and an increased BMI caused by an atypical antipsychotic can be significant, particularly for certain drugs such as olanzapine. Yang et al. found that after 12 weeks of olanzapine therapy, the subjects’ weight increased from 49.75 ±6.34 to 55.37±7.20 and their BM increased from 19.51±2/64 to 21.71±2.86.55

Other Adverse Effects

Other adverse effects include anticholinergic signs/symptoms, dysphagia and aspiration, CNS depression, hepatic and renal dysfunction, falls and fractures, hematologic disorders including (but not limited to) agranulocytosis and neutropenia, orthostatic hypotension, prolonged QT syndrome, and sexual dysfunction.2,56-58 The incidence of these adverse effects varies from drug to drug (e.g., neutropenia is a common adverse effect of clozapine), hepatic and renal dysfunction are very uncommon, and some of these adverse effects only occur in specific patient populations or if risk factors like specific electrolyte abnormalities are present.

Example: All the atypical antipsychotics can cause QTc prolongation, and QTc prolongation is a risk factor for torsades de pointes. The incidence of torsades de pointes associated with the atypical antipsychotics is not known, but it is rare,59 and a prolonged QTc is only one of many factors that can precipitate torsades de pointes in a patient taking an atypical antipsychotic.

Atypical Antipsychotics and Suicide

The atypical antipsychotics are not categorized as antidepressants, but some have a labeled use for treating patients who have major depressive disorder. The prescribing information for these drugs has a US Boxed Warning that advises clinicians that in the first few weeks of treatment, children, adolescents, and adults 18-24 are at risk for suicidal behavior and ideation. The role of medications in decreasing or increasing the risk for suicide is complex, but clozapine has a labeled use for reducing the risk of suicide in patients who have schizophrenia or schizoaffective disorder, and there is evidence that some of the other atypical antipsychotics decrease the risk of suicide.60,61

Nursing Considerations

Patient Safety

Drowsiness and orthostatic hypotension are common adverse effects of the  atypical antipsychotics, and these medications are associated with a risk for falls. Patients who are receiving an atypical antipsychotic should have a routine assessment of ambulatory status/ability, neurological status, and orthostatic vital signs.

Extrapyramidal Syndromes

Extrapyramidal symptoms cannot be completely prevented, but assessment for their presence and early detection may help lessen the consequences. Three important points to remember:

  1. The signs and symptoms of EPS syndrome may be subtle and non-specific, and;
  2. The onset of EPS can be very delayed, and;
  3. EPS can occur when use of the drug is stopped, the dose is increased, or when another medication has been added to the patient’s regimen.

Metabolic Considerations

Weight, serum glucose, serum cholesterol, serum lipids, and serum prolactin should be periodically checked.

QTc Prolongation and Torsades de Pointes

The physician should be notified if the patient has hypocalcemia, hypokalemia, or hypomagnesemia if the QTc > 500 msec or > 60 msec above the patient’s baseline. If a new medication is prescribed, check to see if it may affect the pharmacokinetics of the atypical antipsychotic.

Example: Fluoxetine is a strong inhibitor of CYP2D6 and iloperidone is a substrate of this enzyme. Concurrent use of these medications could increase the serum level of iloperidone.62

Discontinuing Therapy

Abruptly stopping the use of an atypical antipsychotic may cause a discontinuation syndrome that can have significant clinical effects.63,64 Therapy with an atypical antipsychotic should be discontinued slowly, and the dose should be gradually tapered.2

Patient Education

The patient who is receiving an atypical antipsychotic should be informed about the signs and symptoms of metabolic disturbances, EPS, CNS depression, and orthostatic hypotension. The patient may be able to detect subtle, early symptoms of these adverse effects before they are noticed by the nurse. Second, these adverse effects are often the reason for non-compliance with and discontinuation, so early detection is important.

Case Study #1

A 15-year-old male, S.L., has been diagnosed with type I bipolar disorder, and he was prescribed lithium carbonate, 600 mg in divided doses. The patient’s symptoms of depression and mania were lessened, but not to an optimal degree, and the dose of lithium was gradually increased to 1200 mg a day, This seemed to help, but the increased dose also caused nausea and anorexia. In response, the psychiatrist decided to reduce the lithium dose and to prescribe olanzapine,  starting at 2.5 mg a day and increasing to 10 mg a day. After a month of taking lithium and olanzapine the patient reported that his feelings of depression and mania were much less frequent and less severe but he has gained 15 pounds, and his serum glucose is 142 mg/dL, and his serum triglycerides are 175 mg/dL. The psychiatrist is concerned about the laboratory values and the possibility that the patient will stop taking the olanzapine because of the weight; abruptly stopping the drug may worsen his bipolar disorder and possibly cause discontinuation syndrome. The psychiatrist decided to taper the dose of olanzapine slowly and to prescribe aripiprazole; this drug is reported to be much less likely than olanzapine to cause weight gain and other metabolic derangements. After two months the patient’s serum glucose and serum triglycerides are within normal limits, as are all other blood studies, and he is back to his original weight. He is doing well socially and in school and objectively and subjectively his depression and mania are much less frequent and severe.

Case Study #2

M.B. is a 79-year-old female who was recently diagnosed with Alzheimer’s disease and Alzheimer’s related dementia. She has been a resident at a local nursing home for two months, and until recently she has seemed to be  content with her daily routine, but for the past week, she has had intermittent episodes of agitation and several severe emotional outbursts. During one of these episodes, she struck a staff member. Despite several weeks of non-pharmacological interventions, the patient’s behavioral and emotional status worsened, and she started  on risperidone. Prior to starting the drug, a physical examination was performed, a 12-lead ECG was done, serum glucose, calcium, magnesium, and potassium were measured, and a lipid panel was done. Ambulatory status was assessed, body weight was measured, and orthostatic vital signs were checked. Her medication profile was carefully reviewed. After reviewing the data, the psychiatrist decided that it would be safe to begin therapy with risperidone. After several weeks of receiving the drug, the staff noted a significant improvement, but they continued to monitor the patient for adverse effects, and routine ECG and laboratory and assessments were continued.

Select one of the following methods to complete this course.

Take TestPass an exam testing your knowledge of the course material.
OR
Reflect on Practice ImpactDescribe how this course will impact your practice.   (No Test)

References

  1. Nucifora, FC, Mihaljevic M, Lee BJ, Sawa A. Clozapine as a model for antipsychotic development. Neurotherapeutics. 2017;14(3):750-761 (Visit Source).
  2.  Jibson, M.D. Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects. UpToDate , May 15, 2017. Retrieved December 31, 2018 from (Visit Source).
  3. Kapitanyan R, Su M. Second generation (atypical) antipsychotic medication poisoning. UpToDate. January 3, 2018. Retrieved December 31, 2018 from (Visit Source).  
  4. Lewis, JC (2018) Antipsychotic drugs, including phenothiazines. In:  Olson KR, Anderson IB, Benowitz, N.L., Blanc, P.D., Clark, R.F., Kearney, T.E., Kim-Katz, S.Y., Wu, A.H.B., eds. Poisoning & Drug Overdose, 7th ed. McGraw-Hill Education: New York, NY; 2018:130-132.
  5. Beach SR, Celano CM, Sugrue AM, et al. (2018). QT prolongation, torsades de pointes, and psychotropic medications: A 5-year update. Psychosomatics. 2018; 59(2):105-122 (Visit Source).
  6. Stoner SC. Management of serious cardiac adverse effects of antipsychotic medications. Ment Health Clin. 2018;7(6):246-254 (Visit Source).
  7. Radhakrishnan R, Ganesh S, Meltzer HY, Bobo WV, Heckers SH, Fatemi HS, D'Souza, DC. (2019). Schizophrenia. In: Ebert MH, Leckman JF, Petrakis IL., eds. Current Diagnosis & Treatment: Psychiatry, 3e. New York, NY: McGraw-Hill Education; online edition. Retrieved December 31, 2018 from (Visit Source).
  8. Stroup TS, Marder S. Pharmacotherapy for schizophrenia: Acute and maintenance phase treatment. UpToDate. May 23, 2017. Retrieved December 31, 2018 from (Visit Source). 
  9. Andrade C. Antipsychotic drugs in schizophrenia: Relative effects in patients with and without treatment resistance. J ClinPsychiatry. 2016;77(12): e1656-e1660 (Visit Source).
  10. Martino D, Morgante F. Movement disorders and chronic psychosis: Five new things. Neurol Clin Pract. 2017;7(2):163-169 (Visit Source).
  11. Solmi M, Murru A, Pacchiarotti I. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Ther Clin Risk Manag. 2017;13:757-777 (Visit Source).
  12. Stegmayer K, Walther S, van Harten P. Tardive dyskinesia associated with atypical antipsychotics: Prevalence, mechanisms and management strategies. CNS Drugs. 2018 32(2):135-147 (Visit Source).
  13. Lee ES, Vidal C, Findling RL A focused review on the treatment of pediatric patients with atypical antipsychotics. J Child Adolesc Psychopharmacol, 2018;28(9):582-605 (Visit Source).
  14. Dikeç G, Arabaci LB, Uzunoglu GB, Mizrak SD. An investigation of cardiovascular risks in a group of children and adolescents who use atypical antipsychotics. Issues Ment Health Nurs, 2017;38(10):872-880 (Visit Source).
  15. Pillay J, Boylan K, Carrey N, et al. First-and second-generation antipsychotics in children and young adults: systematic review update. Rockville, MD: Agency for Healthcare Research and Quality; March 2017. Retrieved January 1, 2019 from (Visit Source). 
  16. Lemay CA, Mazor KM, Field TS, et al. Knowledge of and perceived need for evidence-based education about antipsychotic medications among nursing home leadership and staff. J Am Med Dir Assoc. 2013;14(12): 895-900 (Visit Source).
  17. Katzung BG, Kruidering-Hall M, Trevor AJ. (2019). Chapter 29: Antipsychotic agents & lithium. In: Katzung & Trevor’s Pharmacology: Examination & Board Review. 12th ed. New York, NY: McGraw-Hill Education. Online version. Retrieved December 31, 2018 from (Visit Source). 
  18. Aringhieri S, Carli M, Kolachalam S, et al. Molecular targets of atypical antipsychotics: From mechanism of action to clinical differences. Pharmacol Ther. 2018; 192:20-41 (Visit Source).
  19. Gareri P, Segura-García C, Manfredi VG et al. Use of atypical antipsychotics in the elderly: a clinical review. Clin Interv Aging. 2014;9:1363-1373 (Visit Source).
  20. Lauriello J, Campbell AR. Pharmacotherapy for schizophrenia: Long-acting injectable antipsychotic drugs. UpToDate. July 5, 2017. Retrieved from (Visit Source). 
  21. Pilon D, Alcusky M, Xiao Y, et al.  Adherence, persistence, and inpatient utilization among adult schizophrenia patients using once-monthly versus twice-monthly long-acting atypical antipsychotics. J Med Econ. 2018;21(2):135-143 (Visit Source).
  22. Yan T, Greene M, Chang E, Hartry A, Touya M, Broder MS. (2018). Medication adherence and discontinuation of aripiprazole once-monthly 400 mg (AOM 400) versus oral antipsychotics in patients with schizophrenia or bipolar I disorder: A real-world study using US claims data. Adv Ther. 2018 Sep 11. doi: 10.1007/s12325-018-0785-y. [Epub ahead of print] (Visit Source).
  23. Press D, Alexander M. Management of neuropsychiatric symptoms of dementia. UpToDate. November 9, 2018. Retrieved January 1, 2019 from (Visit Source). 
  24. American Geriatrics Society 2015 Beers Criteria Expert Panel.  American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2015;63(11):2227-2246 (Visit Source).
  25. Smeets CHW, Zuidema SU, Hulshof TA, et al.  Efficacy of antipsychotics in dementia depended on the definition of patients and outcomes: a meta-epidemiological study. J Clin Epidemiol. 2018;101:17-27 (Visit Source).
  26. Sturm AS, Trinkley KE, Porter K, Nahata MC. Efficacy and safety of atypical antipsychotics for behavioral symptoms of dementia among patients residing in long-term care. Int J Clin Pharm. 2018;40(1):135-142 (Visit Source).
  27. Trinkley KE, Sturm AM, Porter K, Nahata MC. Efficacy and safety of atypical antipsychotics for behavioral and psychological symptoms of dementia among community dwelling adults. J Pharm Pract. 2018 Jan 1:897190018771272. doi: 10.1177/0897190018771272. [Epub ahead of print] (Visit Source).
  28. Maust DT, Kim HM, Seyfried LS, et al. Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. JAMA Psychiatry. 2015;72(5):438-445 (Visit Source).
  29. Huang KL, Fang CJ, Hsu CC, Wu SI, Juang JJ, Stewart R. Myocardial infarction risk and antipsychotics use revisited: a meta-analysis of 10 observational studies. J Psychopharmacol. 2017;31(12):1544-1555 (Visit Source).
  30. Stepnicki P, Kondej M, Kaczor AA. Current concepts and treatments of schizophrenia. Molecules. 2018 Aug 20;23(8). pii: E2087. doi: 10.3390/molecules23082087 (Visit Source).
  31. Pringsheim T, Gardner D, Addington D, et al. The assessment and treatment of antipsychotic-induced akathisia. Can J Psychiatry. 2018 Jan 1:706743718760288. doi: 10.1177/0706743718760288. [Epub ahead of print]
  32. Caroff SN, Campbell EC (2016). Drug-induced extrapyramidal syndromes: Implications for contemporary practice. Psychiatr Clin North Am, 39(3):391-411 (Visit Source).
  33. Salem, H., Nagpal, C., Pigott. T., Teixeira, A.L. (2017). Revisiting antipsychotic-induced akathisia: Current issues and prospective challenges. Curr Neuropharmacol. 15(5):789-798 (Visit Source).
  34. Tarsy, D., Deik, A. (2018). Tardive dyskinesia: Etiology, risk factors, clinical features, and diagnosis. UpToDate. June 19, 2018. Retrieved January 2, 2019 from (Visit Source) cal approach to akathisia.. 
  35. Pieters LE, Bakker PR, van Harten PN Asymmetric drug-induced Parkinsonism and psychopathology: A prospective naturalistic study in long-stay psychiatric patients. Front Psychiatry. 2018 Feb 5;9:18. doi: 10.3389/fpsyt.2018.00018. eCollection 2018.
  36. Ward KM, Citrome L. Antipsychotic-related movement disorders: Drug-induced Parkinsonism vs. tardive dyskinesia-Key differences in pathophysiology and clinical management. Neurol Ther. 2018 Jul 19. doi: 10.1007/s40120-018-0105-0. [Epub ahead of print]
  37. Olanow CW, Klein C, Obeso JA. Chapter 428: Tremor, chorea, and other movement disorders. In: Jameson JL, Fauci AS, Kaper DL, Hauser SL, Longo DL, Loscalzo J, eds. Harrison's Principles of Internal Medicine. 20th ed.  New York, NY: McGraw-Hill Education; 2018. Online version. Retrieved online from (Visit Source).   
  38. Tarsy D. Tardive dyskinesia: Prevention, prognosis, and treatment. UpToDate. June 19, 2018. Retrieved online January 2, 2019 from (Visit Source). 
  39. Jan, R., Correll, C.U. (2018). Tardive dyskinesia: Recognition, patient assessment, and differential diagnosis. J Clin Psychiatry. 2018 Mar/Apr;(2). pii: nu17034ah1c. doi: 10.4088/JCP.nu17034ah1c. Epub 2018 Mar 20.
  40. Carbon M, Kane JM, Leucht S, Correll CU. Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis. World Psychiatry, 2018;17(3):330-340 (Visit Source).
  41. Ware MR, Feller DB, Hall KL Neuroleptic malignant syndrome: Diagnosis and management. Prim Care Companion CNS Disord. 2018 Jan 4;20(1). pii: 17r02185. doi: 10.4088/PCC.17r02185 (Visit Source).
  42. Lommel KM, Meadows AL, Chopra N, Thompson S. Psychiatric emergencies: Serotonin syndrome and neuroleptic malignant syndrome. In: Stone CK, Humphries RL, eds. (2017). Psychiatric emergencies. In: Current Diagnosis & Treatment: Emergency Medicine, 8th ed. New York, NY: McGraw-Hill Education; 2017. Online edition. Retrieved January 2, 2019 from (Visit Source).
  43. Wijdicks EFM. Neuroleptic malignant syndrome. UpToDate. November 27, 2017. Retrieved January 2, 2019 from (Visit Source). 
  44. Wang C, Shi W, Huang C, Zhu J, Huang W, Chen G. The efficacy, acceptability, and safety of five atypical antipsychotics in patients with first-episode drug-naïve schizophrenia: a randomized comparative trial. Ann Gen Psychiatry. 2017 Dec 22;16:47. doi: 10.1186/s12991-017-0170-2. eCollection 2017 (Visit Source).
  45. Ribeiro SB, de Araújo AA, Medeiros CA, et al. Factors associated with expression of extrapyramidal symptoms in users of atypical antipsychotics. Eur J Clin Pharmacol. 2017;73(3):351-355 (Visit Source).
  46. Kowalchuk C, Castellani L, Chintoh A, Remington G, Giacca A, Hahn M.  Antipsychotics and glucose metabolism: how brain and body collide. Am J Physiol Endocrinol Metab 2018;316(1): E1-E15 (Visit Source).
  47. Lee H, Song DH, Kwon JW, Han E, Chang MJ, Kang HY. Assessing the risk of type 2 diabetes mellitus among children and adolescents with psychiatric disorders treated with atypical antipsychotics: a population-based nested case-control study. Eur Child Adolesc Psychiatry, 2018;27(10):1321-1334 (Visit Source).
  48. Bent-Ennakhil N, Cécile Périer M, Sobocki P, et al. Incidence of cardiovascular diseases and type-2-diabetes mellitus in patients with psychiatric disorders. Nord J Psychiatry. 2018;4:1-7 (Visit Source).
  49. Kato Y, Umetsu R, Abe J, et al. Hyperglycemic adverse events following antipsychotic drug administration in spontaneous adverse event reports. J Pharm Health Care Sci. 2015;16:1:15 (Visit Source).
  50. Vuk A, Baretic M, Osvatic MM, Filipcic I, Jovanovic N, Kuzman MR.  Treatment of diabetic ketoacidosis associated with antipsychotic medication: Literature review. J Clin Psychopharmacol, 2017;37(5):584-589 (Visit Source).
  51. Bishara A, Phan SV, Young HN, Liao TV. Glucose disturbances and atypical antipsychotic use in the intensive care unit. J Pharm Pract. 2016;29(6):534-538 (Visit Source).
  52. Ribeiro ELA, de Mendonça Lima T, Vieira MEB, Storpirtis S, Aguiar PM. Efficacy and safety of aripiprazole for the treatment of schizophrenia: an overview of systematic reviews. Eur J Clin Pharmacol. 2018;74(10):1215-1233 (Visit Source).
  53. Wei Xin Chong J, Hsien-Jie Tan E, Chong CE, Ng Y, Wijesinghe R. Atypical antipsychotics: A review on the prevalence, monitoring, and management of their metabolic and cardiovascular side effects. Ment Health Clin. 2016;6(4):178-184.
  54. De Hert M, Peuskens J, Sabbe T, et al. Relationship between prolactin, breast cancer risk, and antipsychotics in patients with schizophrenia: a critical review. Acta Psychiatr Scand. 2016;133(1):15-22 (Visit Source).
  55. Yang F, Chen L, Fang X, et al. Influence of olanzapine on serum prolactin levels and BMI in female patients with schizophrenia. Neuropsychiatr Dis Treat. 2018;13;14:3373-3379. doi: 10.2147/NDT.S180303. eCollection 2018 (Visit Source).
  56. Slim M, Medina-Caliz I, Gonzalez-Jimenez A, et al. Hepatic safety of atypical antipsychotics: Current evidence and future directions. Drug Saf. 2016;39(10):925-943 (Visit Source).
  57. Jiang Y, McCombs JS, Park SH, et al. A retrospective cohort study of acute kidney injury risk associated with antipsychotics. CNS Drugs. 2017;31(4):319-326 (Visit Source).
  58. Ryan PB, Schuemie MJ, Ramcharran D, Stang PE. Atypical antipsychotics and the risks of acute kidney injury and related outcomes among older adults: A replication analysis and an evaluation of adapted confounding control strategies. Drugs Aging. 2017;34(3):211-219.
  59. Arunachalam K, Lakshmanan S, Maan A, Kumar N, Dominic P. Impact of drug induced long QT syndrome: A systematic review. J Clin Med Res. 2018;10(5):384-390 (Visit Source).
  60. Ma CH, Chang SS, Tsai HJ, et al. Comparative effect of antipsychotics on risk of self-harm among patients with schizophrenia. Acta Psychiatr Scand, 2018;137(4):296-305 (Visit Source).
  61. Pompili M, Baldessarini RJ,  Forte A, et al. Do atypical antipsychotics have antisuicidal effects? A hypothesis-generating overview. Int J Mol Sci. 2016 Oct 11;17(10). pii: E1700 (Visit Source).
  62. UpToDate. Lexicomp® Drug Interactions: Iloperidone. Retrieved January 5, 2019 from (Visit Source). 
  63. Takeuchi H, Kantor N, Uchida H, Suzuki T, Remington G. Immediate vs gradual discontinuation in antipsychotic switching: A systematic review and meta-analysis. Schizophr Bull. 2017;43(4):862-871 (Visit Source).
  64. Salomon C, Hamilton B, Elsom S. Experiencing antipsychotic discontinuation: results from a survey of Australian consumers. J Psychiatr Ment Health Nurs. 2014;21(10):917-923 (Visit Source).